FULL-TEXT ARTICLE
Markers of HIV reservoir size and immune activation
after treatment in acute HIV infection with and without
raltegravir and maraviroc intensification.
Ananworanich J, Chomont N, Fletcher JL,
et al
J Virus Erad.
2015;1(2):116-122.
Paper
Lipid Changes in Virologically Suppressed HIV-Infected
Patients Switching from any Antiretroviral Therapy to
the Emtricitabine/Rilpivirine/Tenofovir Single Tablet:
GeSida Study 8114.
Palacios R, Mayorga M, Pérez-Hernández IA, Rivero A,
et al
J Int Assoc Provid AIDS Care.
2016 Feb 8.
Abstract
Tenofovir DF/emtricitabine and efavirenz combination
therapy for HIV infection in patients treated for
tuberculosis: the ANRS 129 BKVIR trial.
Lortholary
O, Roussillon C, Boucherie C, et al
J Antimicrob Chemother.
2015 Dec 17.
Abstract
Patient-reported outcomes in the single-tablet regimen (STaR)
trial of rilpivirine/emtricitabine/tenofovir disoproxil
fumarate versus efavirenz/emtricitabine/tenofovir
disoproxil fumarate in antiretroviral treatment-naive
adults infected with HIV-1 through 48 weeks of
treatment.
Wilkins EL, Cohen CJ, Trottier B, et al
AIDS Care. 2015 Oct
21:1-8
Abstract
Comparison of HIV Virologic Failure Rates
Between Patients with Variable Adherence to Three
Antiretroviral Regimen Types.
Gordon LL, Gharibian D,
Chong K, Chun H.
AIDS Patient Care STDS.
2015 Jul;29(7):384-388.
Abstract
Rilpivirine Versus Efavirenz with
Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve
HIV-1-Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96
Pooled ECHO/THRIVE Subanalysis.
Behrens G,
Rijnders B, Nelson M, et al
AIDS Patient Care STDS. 2014
Apr;28(4):168-75.
Abstract
Week 48 results from a randomized clinical trial of
rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs.
efavirenz/emtricitabine/tenofovir disoproxil fumarate in
treatment-naive HIV-1-infected adults.
Cohen C, Wohl D, Arribas JR, Henry K, et
al
AIDS. 2014 Feb 6
Abstract
A Randomized Double-Blind Comparison of Coformulated
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus
Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of
HIV-1 Infection: Analysis of Week 96 Results.
Zolopa A, Sax PE, Dejesus E, et
al
J Acquir Immune Defic Syndr. 2013 May
1;63(1):96-100.
Abstract |
A randomized, double-blind comparison of co-formulated
elvitegravir/cobicistat/emtricitabine/tenofovir DF versus
efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection:
analysis of week 96 results.
Zolopa A, Sax PE, Dejesus E, et
al
J Acquir Immune Defic Syndr.
2013 Feb 7.
Abstract
|
A randomized, double-blind comparison of co-formulated
elvitegravir/cobicistat/emtricitabine/tenofovir versus ritonavir-boosted
atazanavir plus co-formulated emtricitabine and tenofovir DF for initial
treatment of HIV-1 infection: analysis of week 96 results.
Rockstroh JK, Dejesus E, Henry K, et al
J Acquir Immune Defic Syndr.
2013 Jan 18
Abstract |
Effectiveness and safety of a single-tablet regimen of
emtricitabine/efavirenz/tenofovir in HIV-1-infected patients in infectious
diseases department.
Xerinda S, Neves N, Santos S, et al.
J Int AIDS Soc.
2012 Nov 11;15(6):18383.
Abstract
FULL-TEXT ARTICLE
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of
HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings.
Campbell TB, Smeaton LM, Kumarasamy N,
et al
PLoS Med. 2012
Aug;9(8):e1001290.
Paper
Discontinuation of Atripla as first-line therapy in HIV-1
infected individuals.
Scourfield A, Zheng J, Chinthapalli S, et al
AIDS.
2012 Mar 21
Abstract
Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
Single-Tablet Regimen (Atripla®):A Review of its Use in the
Management of HIV Infection.
Deeks ED, Perry CM
Drugs. 2010
Dec 3;70(17):2315-2338.
Abstract |
Documents identified with this icon are in Portable Document Format (PDF)
and require the
